Drugs / Typhoid Vi conjugate vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07663032 Comparator | Jun 2026 → Nov 2027 expected | salmonellosis | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Typhoid Vi conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07663032 ↗ |
| Modality | Vaccine | “Typhoid Vi conjugate vaccine as control” NCT07663032 ↗ |